Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827404 | 1.00 | SCD (0.41) | SCDSUCNR1MAPTNPSR1KDM4E | |
| SCHEMBL23838022 | 0.93 | MAPT (0.41) | SCDMAPTNPSR1KDM4ELMNA | |
| SCHEMBL22013230 | 0.93 | MAPT (0.41) | SCDMAPTNPSR1KDM4ELMNA | |
| SCHEMBL20566583 | 0.87 | SUCNR1 (0.42) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL20566580 | 0.87 | SUCNR1 (0.42) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL23827383 | 0.85 | SCD (0.39) | SCDSUCNR1MAPTNPSR1KDM4E | |
| SCHEMBL23827381 | 0.85 | SCD (0.39) | SCDSUCNR1MAPTNPSR1KDM4E | |
| SCHEMBL22013868 | 0.81 | MAPT (0.40) | SCDMAPTNPSR1KDM4ETDP1 | |
| SCHEMBL20565953 | 0.80 | CA12 (0.41) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL20565954 | 0.80 | CA12 (0.41) | SUCNR1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171014-B | Monocyclolactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-112771040-B | Monocyclic lactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3882246-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| CN-112771040-A | Monocyclic lactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-111171014-A | Monocyclic lactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | BPGM, IL1B, WEE1 | SCD 511/4885SUCNR1 1018/4885MAPT 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.